264 related articles for article (PubMed ID: 35629099)
1. The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia.
Khan AM
J Pers Med; 2022 Apr; 12(5):. PubMed ID: 35629099
[TBL] [Abstract][Full Text] [Related]
2. The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia.
Ababneh O; Abushukair H; Qarqash A; Syaj S; Al Hadidi S
Clin Hematol Int; 2022 Jun; 4(1-2):21-29. PubMed ID: 35950210
[TBL] [Abstract][Full Text] [Related]
3. Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia: A review.
Moore DC
J Oncol Pharm Pract; 2021 Dec; 27(8):1993-1999. PubMed ID: 34558376
[TBL] [Abstract][Full Text] [Related]
4. Managing Waldenström's macroglobulinemia with BTK inhibitors.
Buske C; Jurczak W; Salem JE; Dimopoulos MA
Leukemia; 2023 Jan; 37(1):35-46. PubMed ID: 36402930
[TBL] [Abstract][Full Text] [Related]
5. Waldenström's macroglobulinemia - clinical symptoms and review of therapy yesterday, today and tomorrow.
Adam Z; Pour L; Zeman D; Krejčí M; Boichuk I; Krejčí M; Štork M; Sandecká V; Král Z
Klin Onkol; 2023; 36(3):177-191. PubMed ID: 37353346
[TBL] [Abstract][Full Text] [Related]
6. The Management of Relapsed or Refractory Waldenström's Macroglobulinemia.
García-Sanz R; Tedeschi A
Hematol Oncol Clin North Am; 2023 Aug; 37(4):727-749. PubMed ID: 37246089
[TBL] [Abstract][Full Text] [Related]
7. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.
Tawfiq RK; Abeykoon JP; Kapoor P
Curr Hematol Malig Rep; 2024 Jun; 19(3):120-137. PubMed ID: 38536576
[TBL] [Abstract][Full Text] [Related]
8. The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia.
Gavriatopoulou M; Fotiou D; Ntanasis-Stathopoulos I; Dimopoulos MA
Expert Rev Anticancer Ther; 2020 Aug; 20(8):663-674. PubMed ID: 32631091
[TBL] [Abstract][Full Text] [Related]
9. Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.
Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Investig Drugs; 2017 Feb; 26(2):197-205. PubMed ID: 28043164
[TBL] [Abstract][Full Text] [Related]
10. Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia).
Bou Zerdan M; Valent J; Diacovo MJ; Theil K; Chaulagain CP
Adv Hematol; 2022; 2022():1182384. PubMed ID: 35096069
[TBL] [Abstract][Full Text] [Related]
11. A safety profile of medications used to treat Waldenström's macroglobulinemia.
García-Sanz R; Jiménez C; González De La Calle V; Sarasquete ME
Expert Opin Drug Saf; 2018 Jun; 17(6):609-621. PubMed ID: 29768934
[TBL] [Abstract][Full Text] [Related]
12. First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis.
Abushukair H; Syaj S; Ababneh O; Qarqash A; Schinke C; Thanendrarajan S; Zangari M; van Rhee F; Al Hadidi S
Am J Hematol; 2022 Jul; 97(7):942-950. PubMed ID: 35358350
[TBL] [Abstract][Full Text] [Related]
13. [The efficacy and safety of Bruton tyrosine kinase inhibitors as monotherapy in the treatment of newly diagnosed patients with Waldenström macroglobulinemia].
Tao Y; Xu YL; Wang S; Wang L; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):490-494. PubMed ID: 37550205
[No Abstract] [Full Text] [Related]
14. Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients.
D'Sa S; Matous JV; Advani R; Buske C; Castillo JJ; Gatt M; Kapoor P; Kersten MJ; Leblond V; Leiba M; Palomba ML; Paludo J; Qiu L; Sarosiek S; Shadman M; Talaulikar D; Tam CS; Tedeschi A; Thomas SK; Tohidi-Esfahani I; Trotman J; Varettoni M; Vos J; Garcia-Sanz R; San-Miguel J; Dimopoulos MA; Treon SP; Kastritis E
Semin Hematol; 2023 Mar; 60(2):80-89. PubMed ID: 37147252
[TBL] [Abstract][Full Text] [Related]
15. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia.
Sarosiek S; Sermer D; Branagan AR; Treon SP; Castillo JJ
Expert Rev Anticancer Ther; 2022 May; 22(5):471-478. PubMed ID: 35404729
[TBL] [Abstract][Full Text] [Related]
16. Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First.
Deshpande A; Munoz J
Ther Clin Risk Manag; 2022; 18():657-668. PubMed ID: 35770040
[TBL] [Abstract][Full Text] [Related]
17. Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies.
Abbas HA; Wierda WG
Front Oncol; 2021; 11():668162. PubMed ID: 34055635
[TBL] [Abstract][Full Text] [Related]
18. A fatal disseminated cryptococcal infection in a patient treated with zanubrutinib for Waldenström's macroglobulinemia.
Patel D; Sidana M; Mdluli X; Patel V; Stapleton A; Dasanu CA
J Oncol Pharm Pract; 2022 Dec; 28(8):1917-1921. PubMed ID: 35306909
[TBL] [Abstract][Full Text] [Related]
19. Current and novel BTK inhibitors in Waldenström's macroglobulinemia.
Ntanasis-Stathopoulos I; Gavriatopoulou M; Fotiou D; Dimopoulos MA
Ther Adv Hematol; 2021; 12():2040620721989586. PubMed ID: 33613931
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib-Associated Skin Toxicity: A Case of Maculopapular Rash in a 79-Year Old Caucasian Male Patient with Relapsed Waldenstrom's Macroglobulinemia and Review of the Literature.
Jensen AB; Stausbøl-Grøn B; Riber-Hansen R; d'Amore F
Dermatol Reports; 2017 Mar; 9(1):6976. PubMed ID: 28469834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
